<DOC>
	<DOCNO>NCT00470236</DOCNO>
	<brief_summary>Hypotheses : 1 . The addition tumour bed boost BCS woman non-low risk DCIS reduce risk local recurrence ( invasive intraductal recurrence ipsilateral breast ) . 2 . The risk local recurrence short fractionation arm bad standard fractionation arm . 3 . A molecular signature predictive invasive recurrence DCIS detectable molecular signature may eventually clinical utility therapy individualization . Overall Objectives : 1 . To improve outcome woman non-low risk DCIS treat breast conserving therapy . 2 . To individualize treatment selection woman DCIS achieve long term disease control minimal toxicity .</brief_summary>
	<brief_title>Radiation Doses Fractionation Schedules Non-low Risk Ductal Carcinoma In Situ ( DCIS ) Breast</brief_title>
	<detailed_description>Specific objective : 1 . To evaluate time local recurrence woman DCIS treat breast conserving surgery follow : - whole breast RT alone versus whole breast RT plus tumour bed boost ; - RT use standard fractionation schedule versus short schedule . 2 . To evaluate time disease recurrence overall survival woman DCIS treat breast conserving surgery follow : - whole breast RT alone versus whole breast RT plus tumour bed boost ; - RT use standard fractionation schedule versus short schedule . 3 . To compare toxicity : - whole breast RT alone versus whole breast RT plus tumour bed boost ; - RT use standard fractionation schedule versus short schedule . 4 . To compare cosmetic outcome : - whole breast RT alone versus whole breast RT plus tumour bed boost ; - RT use standard fractionation schedule versus short schedule . 5 . To identify molecular signature predictive invasive recurrence DCIS facilitate therapy individualization . 6 . To assess inter-relationship biomarkers relationship biomarker expression specific histopathologic feature DCIS . 7 . To evaluate quality life woman treat : - whole breast RT alone versus whole breast RT plus tumour bed boost ; - RT use standard fractionation schedule versus short schedule .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<criteria>Patients must fulfill follow criterion admission study : Women ≥ 18 year . Histologically proven DCIS breast without invasive component . Bilateral mammogram perform within 6 month prior randomization . Clinically nodenegative . Treated breast conserve surgery ( primary excision reexcision ) complete microscopic excision clear radial margin ≥1 mm* ( *Patients superficial deep resection margin &lt; 1 mm eligible surgery remove intervene breast tissue subcutaneous tissue pectoralis fascia ) . Women high risk local recurrence due : Age &lt; 50 year ; OR Age ≥ 50 year plus least one following : Symptomatic presentation Palpable tumour Multifocal disease Microscopic tumour size ≥ 1.5 cm maximum dimension Intermediate high nuclear grade Central necrosis Comedo histology Radial* surgical resection margin &lt; 10 mm . ( *Patients superficial deep resection margin &lt; 10 mm eligible surgery remove intervene breast tissue subcutaneous tissue pectoralis fascia . ) Assessed surgeon radiation oncologist suitable breast conserve therapy include whole breast RT . Ability tolerate protocol treatment . Protocol RT preferably commence within 8 week must commence later 12 week last surgical procedure . ECOG performance status 0 , 1 2 . Patient 's life expectancy &gt; 5 year . Availability longterm followup . Written informed consent . Patients fulfill follow criterion eligible admission study : Multicentric disease extensive microcalcifications could completely excise breast conserve surgery radial margin ≥1 mm* . *Patients superficial and/or deep margin &lt; 1 mm eligible surgery remove intervene breast tissue subcutaneous tissue pectoralis fascia . Presence tumour cell lymph node detect use H &amp; E immunohistochemical examination ( lymph node biopsy dissection perform ) . Locally recurrent breast cancer . Previous DCIS invasive cancer contralateral breast . Bilateral DCIS breast Synchronous invasive carcinoma contralateral breast Other concurrent previous malignancy except : Nonmelanomatous skin cancer ; Carcinoma situ cervix endometrium ; Invasive carcinoma cervix , endometrium , colon , thyroid melanoma treat least five year prior study admission without disease recurrence . Serious nonmalignant disease precludes definitive surgical radiation treatment ( e.g. , scleroderma , systemic lupus erythematosus , cardiovascular/pulmonary/renal disease ) . ECOG performance status ≥ 3 . Women pregnant lactating .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ductal carcinoma in-situ</keyword>
	<keyword>Breast conserving therapy</keyword>
	<keyword>Whole breast radiation therapy</keyword>
	<keyword>Tumour bed boost</keyword>
	<keyword>Fractionation schedule</keyword>
	<keyword>Completely excise non-low risk DCIS</keyword>
</DOC>